Lerodalcibep-Liga
Sold as Lerochol. Every branded application for this active ingredient.
- First approved: Dec 12, 2025
- Branded applications: 1
- New uses approved: 0
- Complete response letters: 1
Applications
NDAs and BLAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 12, 2025 | LerocholBLA 761427 · New molecular entity | Lib Therapeutics, Inc. | 1 | Marketed |
Complete Response Letters
FDA's published letters for these applications| Letter | Product | Now |
|---|---|---|
| Dec 12, 2025 | Lerochol (lerodalcibep-liga)Clinical | Unapproved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA